Candonilimab in Combination With LM-302 for Claudin 18.2 Positive-advanced Biliary Tract Cancer After Failure of Standard of Chemotherapy and PD1/PD-L1 Antibody

NCT05994001 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

78

Enrollment

OTHER

Sponsor class

Conditions

Biliary Tract Cancer
Candonilimab
Claudin 18.2

Interventions

DRUG: cardonilizumab
DRUG: LM-302

Sponsor

Shanghai Zhongshan Hospital